- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03987438
A Behavioral Intervention to Prevent Impaired Glucose Tolerance Diabetes Mellitus (DIGITAL-I)
Diabetes Mellitus, Impaired Glucose Tolerance and Gestational Diabetes Mellitus Intervention Action-Leading Trial- Impaired Glucose Tolerance Study (DIGITAL-I Study)
The national epidemiological survey showed that the prevalence rate of pre-diabetes was up to 35.7% in China. Previous study indicated that lifestyle intervention in people with impaired glucose tolerance could delay the onset of type 2 diabetes. However, patients with pre-diabetes do not pay enough attention to their glucose metabolism, and most of them rarely monitor their blood glucose. With the increasing use of smartphones, mobile applications (APPs) can be applied in the education and management of chronic diseases, including diabetes. Thus, the investigators will conduct a multi-centered, two-armed, open-labeled, randomized controlled trial to evaluate whether the behavioral intervention by a mobile APP can prevent the occurrence of diabetes in people with impaired glucose tolerance.
The investigators hypothesize that behavioral intervention in pre-diabetes with using a mobile APP that incorporates nutrition, exercise and psychological support from trained professional doctors will:
- Reduce the risk of the onset of diabetes in people with impaired glucose tolerance.
- Increase the reversal rate of becoming normal glucose tolerance and reduce the levels of glycosylated hemoglobin in pre-diabetes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants from fourteen research centers in the mainland of China will be recruited in the study. People will be screened for a 75g oral glucose tolerance test (OGTT). The patients whose fasting glucose between 6.1mmol/L and 7.0mmol/L or 2-hour value between 7.8mmol/L and 11.1mmol/L will be diagnosed with impaired glucose tolerance and recommended to participate in the study.
People who meet the eligibility criteria and who are willing to provide informed consent will be enrolled and randomized to behavioral intervention group and control group. People in the behavioral intervention group will be educated and monitored by a mobile APP that provides behavioral support including health knowledge education, mental health counseling, smart diet advice, intelligent exercise guidance, and target weight management. Meanwhile, the behavioral support will be modified by endocrinologists, dieticians, sports medicine professionals and psychologists individually based on the feedback of their characteristics and performance recorded in the APP. Participants randomized to the control group only have regular care in their local hospitals.
Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests, adverse events, combined medications and health checklists. Investigators conduct face-to-face health education, lifestyle guidance and mobile APP software inspection. Every one year, 75g OGTT (0min, 60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated in both of the group. Investigators will compare the diabetes risk in the two groups to evaluate whether behavioral intervention with a mobile APP can reduce the risk of the onset of diabetes in people with impaired glucose tolerance. Investigators also will compare the reversal rate of becoming normal glucose tolerance in prediabetes and the changes of glycosylated hemoglobin levels in both groups. Behavioral intervention with the APP will last for two years.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Tianpei Hong, MD,PhD
- Phone Number: +8615611908212 +8613683265725
- Email: tpho66@bjmu.edu.cn
Study Contact Backup
- Name: Jin Yang, PhD
- Phone Number: +8615810298367
- Email: yangjin@bjmu.edu.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Recruiting
- Peking University Third Hospital YanQing Hospital
-
Contact:
- Jinzhan Song, MS
- Phone Number: +8615811096083
- Email: guliangbiao@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 and 70 years old
- Impaired glucose tolerance will be diagnosed by a 75g OGTT according to the criteria of World Health Organization as a fasting plasma glucose level between 6.1 mmol/L and 7.0 mmol/L, or 2-hour value between 7.8 mmol/L and 11.1 mmol/L
- Willing to keep reading the education articles and supporting materials that delivered by the mobile APP
- Willing to provide informed consent
Exclusion Criteria:
- Pregnant women, pregnant or lactating women (Can be reassessed after childbirth or after breastfeeding)
- Inconvenient to move, far away from the center to limit follow-up, more than 2 hours drive from the center
- Cannot complete the test because of planning migration
- Schizophrenia, manic depression, drug or alcohol addicts
- Cancer patients who have been treated in the past 5 years
- HIV positive (report)
- Active tuberculosis
- Patients with severe CVD (Myocardial infarction, heart failure, stroke) or pulmonary embolism in the past 6 months
- Unstable angina or resting angina; history of cardiac arrest; severe arrhythmia; uncontrolled atrial fibrillation (heart rate not less than 100 beats / min); cardiac function by New York Cardiology Society Grade III ~ IV; acute myocarditis, pericarditis or hypertrophic cardiomyopathy; clinically significant aortic stenosis; severe left bundle branch block or installation of a pacemaker (unless agreed by a cardiologist); history of defibrillation; aortic aneurysm diameter > 7cm or history of aortic rupture; history of heart transplantation; resting heart rate <45 beats / min or > 100 beats / min
- Cirrhosis; Cushing's syndrome; acromegaly; long-term application of glucocorticoids
- Serum creatinine is 2 times higher than the upper limit of normal; currently undergoing dialysis
- Chronic anoxia diseases such as emphysema, pulmonary heart disease, etc.
- Rheumatic heart disease; congenital heart disease
- Organ transplantation patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Behavioral intervention
Participants randomized to the behavioral intervention group will be provided with a mobile APP which incorporates behavioral support including health knowledge education, mental health counseling, diet advice, exercise guidance and weight management.
Meanwhile, the behavioral support will be modified by endocrinologists, dieticians, sports medicine professionals and psychologists individually based on the feedback of their performance recorded in the APP.
Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests and adverse events.
Investigators conduct face-to-face health education, lifestyle guidance, mobile APP software inspection.
Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated.
|
The lifestyle intervention will be launched by an APP installed in participants' private mobile phones, including health knowledge education, mental health counseling, smart diet advice, intelligent exercise guidance, and target weight management.
Nutrition recommendation is conducted according to the Chinese Dietary Guide, Chinese and International Guidelines of Gestation Diabetes Management.
Exercise guidance is given based on the Guidelines for National Fitness of China, Chinese and International Guidelines of Gestation Diabetes Management.
Psychological support is given by sending education articles on mental health.
Participants are encouraged to update data about their diet, exercise and body weight through the APP.
The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together to modify the behavioral supports individually based on the feedback of their characteristics and performance recorded in the APP.
|
No Intervention: Control group
Participants randomized to the control group have regular care in their local hospitals.
Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests and adverse events.
Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The risk of diabetes mellitus (DM) in patients with impaired glucose tolerance
Time Frame: 2 years
|
DM will be diagnosed by a 75g OGTT according to the World Health Organization criteria as fasting plasma glucose level 7.0 mmol/L or more, or 2-hour value 11.1 mmol/L or more.
Investigators will compare the diabetes risk in the two groups to evaluate whether behavioral intervention with a mobile APP can reduce the risk of the onset of diabetes in people with impaired glucose tolerance.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reversal rate of becoming normal glucose tolerance in pre-diabetes
Time Frame: 2 years
|
Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels) will be evaluated in both of the group.
Investigators will compare the reversal rate of becoming normal glucose tolerance in pre-diabetes.
|
2 years
|
Changes in glycosylated hemoglobin levels.
Time Frame: 2 years
|
Glycosylated hemoglobin levels will be recorded at the beginning, middle and end of the study.
Investigators will compare the changes in glycosylated hemoglobin levels.
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tianpei Hong, MD,PhD, Peking University Third Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DIGITAL-I-2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
Clinical Trials on Lifestyle intervention with APP
-
Peking University Third HospitalUnknownDiabetes, GestationalChina
-
The University of Texas Health Science Center at...National Institute on Aging (NIA); The Claude D. Pepper Older Americans Independence...CompletedType 2 Diabetes | Frailty | Weight, BodyUnited States
-
Hubei Hospital of Traditional Chinese MedicineShanxi Provincial Hospital of Traditional Chinese Medicine; Wuhan Hospital... and other collaboratorsUnknown
-
The University of Hong KongSuspendedInsomnia | PreDiabetes | Sleep DeprivationHong Kong
-
Texas Tech UniversityCompleted
-
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical...Completed
-
Chang Gung University of Science and TechnologyCompletedObstructive Sleep ApneaTaiwan
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Maryland Cigarette Restitution FundCompletedKidney Cancer | Breast Cancer | Rectal Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Melanoma (Skin) | Gallbladder CancerUnited States
-
Northumbria UniversityNewcastle University; Versus Arthritis; Teesside UniversityUnknownSjogren's SyndromeUnited Kingdom
-
Masonic Cancer Center, University of MinnesotaNot yet recruitingObesity | Early-stage Breast Cancer